Nothing Special   »   [go: up one dir, main page]

Mandal et al., 2011 - Google Patents

Total chemical synthesis of biologically active vascular endothelial growth factor

Mandal et al., 2011

View HTML
Document ID
17280524385806501732
Author
Mandal K
Kent S
Publication year
Publication venue
Angewandte Chemie International Edition

External Links

Snippet

Vascular endothelial growth factor (VEGF), also known as VEGF-A, is the principal endothelial-cell-specific mitogen that induces embryonic and somatic angiogenesis.[1–4] VEGF also plays an important role in tumor angiogenesis and in proliferative retinopathy.[5] …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Mandal et al. Total chemical synthesis of biologically active vascular endothelial growth factor
Kent Novel protein science enabled by total chemical synthesis
Xiang et al. Proximity‐enabled protein crosslinking through genetically encoding haloalkane unnatural amino acids
Colombo et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif
Blaber et al. X-ray crystal structure of human acidic fibroblast growth factor
Cigler et al. Proximity‐triggered covalent stabilization of low‐affinity protein complexes in vitro and in vivo
Muller et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site
Chen et al. Dithiol amino acids can structurally shape and enhance the ligand-binding properties of polypeptides
Martínez‐Sáez et al. Oxetane Grafts Installed Site‐Selectively on Native Disulfides to Enhance Protein Stability and Activity In Vivo
CN103038249B (en) In conjunction with the tear lipocalin mutain of IL-4 receptor alpha
Wei et al. Molecular organization of the Ndc80 complex, an essential kinetochore component
JP6105479B2 (en) Designed repeat proteins that bind to serum albumin
Ladner et al. Phage display-derived peptides as therapeutic alternatives to antibodies
Bang et al. Total chemical synthesis and X‐ray crystal structure of a protein diastereomer:[D‐Gln 35] ubiquitin
Cahuzac et al. A recurrent RNA‐binding domain is appended to eukaryotic aminoacyl‐tRNA synthetases
Deluigi et al. Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
CN108350054A (en) Bifunctional protein and pharmaceutical composition comprising it
Li et al. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides
Kent Bringing the science of proteins into the realm of organic chemistry: total chemical synthesis of SEP (synthetic erythropoiesis protein)
Zhang et al. Rational design of humanized dual-agonist antibodies
Ebenhoch et al. Crystal structure and receptor-interacting residues of MYDGF—a protein mediating ischemic tissue repair
Dang et al. Elucidation of the covalent and tertiary structures of biologically active Ts3 toxin
Yin et al. Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity
Myrhammar et al. Photocontrolled reversible binding between the protein A-derived Z domain and immunoglobulin G
Tamshen et al. Genetic code expansion enables site-specific PEGylation of a human growth hormone receptor antagonist through click Chemistry